Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer
Patients with PR values <20% tended to have shorter PFS, unlike the Ki-67 value, which did not demonstrate an impact on PFS. This suggests a prognostic value of PR expression levels in this scenario.
Authors
- Francisco Von Stecher (ORCID: https://orcid.org/0000-0001-9018-9449)
- Florencia Perazzo (ORCID: https://orcid.org/0000-0002-4512-7684)
- Fernando Paesani
- G. Colucci
- Pablo Mandó (ORCID: https://orcid.org/0000-0001-8387-9011)
- Maria Vega (ORCID: https://orcid.org/0000-0003-1936-8051)
- Anna Cabané Ballester
- María Florencia Illia
- Mariana Eiben
Institutions
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-08-12
- DOI
- https://doi.org/10.3332/ecancer.2025.1963
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00